Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

  NGX-4010
(n = 102)
Control
(n = 53)
Demographics
Age (yr), mean ± SD 68.7 ± 12.00 71.2 ± 11.26
Male, n (%) 47 (46%) 25 (47%)
Race   
   White 89 (87%) 45 (85%)
   Black or African American 6 (6%) 3 (6%)
   Asian 1 (1%) 1 (2%)
   American Indian or Alaska Native 0 (0%) 1 (2%)
   Native Hawaiian or Other Pacific Islander 0 (0%) 0 (0%)
   Other 6 (6%) 3 (6%)
Clinical characteristics
Duration of Pain (yr), mean ± SD 2.7 ± 2.92 3.4 ± 4.00
Baseline a "Average Pain for the Past 24 Hours", mean ± SD 5.4 ± 1.58 5.3 ± 1.53
On Concomitant Pain Medicationb, n (%) 78 (76%) 42 (79%)
   Opioids 26 (25%) 13 (25%)
   Anticonvulsants 26 (25%) 18 (34%)
   Antidepressants 10 (10%) 6 (11%)
   Other 52 (51%) 30 (57%)
Size of Painful Area at Screening (cm2), mean ± SD 337.9 ± 226.46 334.2 ± 221.92
  1. Baseline pain level was defined as the mean of all available non-biased Screening NPRS scores in that category.
  2. A patient was defined as being on concomitant pain medication if pain medication started prior to day of treatment, continued on the day of treatment, and was taken for at least 7 days.